View article

The soluble receptor for advanced glycation end-products (sRAGE) is a marker of alveolar type I epithelial cell injury associated with clinical outcomes in acute respiratory distress syndrome and, more recently, in hospitalized subjects with COVID-19 (JCI Insight, 2021). How plasma sRAGE changes over time and whether plasma sRAGE remains associated with long-term clinical outcomes beyond a single baseline measurement in patients with COVID-19 has not been well-studied. We studied 131 adult participants receiving high flow nasal oxygen (HFNO) or non-invasive ventilation (NIV) enrolled in a randomized clinical trial of tixagevimab/cilgavimab vs. placebo (Lancet Resp Med, 2023) for patients hospitalized with COVID-19 without organ failure. The relationship between the highest quartile of plasma sRAGE at day 0 and day 3 and 90-day sustained recovery was analyzed using a …